Clovis' Rubraca leads to 44% ORR in Phase II for CRPC

Clovis Oncology Inc. (NASDAQ:CLVS) said twice-daily oral Rubraca rucaparib led to a confirmed objective response rate (ORR) by investigator assessment of 44% in 25 evaluable patients with a BRCA1/2 mutation in the Phase II TRITON2 trial to treat metastatic castration-resistant prostate cancer. The data were presented

Read the full 461 word article

How to gain access

Continue reading with a
two-week free trial.